6-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone | 86798-87-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone
• 英文别名: 6-[4-(2-methyl-1H-imidazol-1-yl)phenyl)-3(2H)-pyridazinone；3-[4-(2-methylimidazol-1-yl)phenyl]-1H-pyridazin-6-one
• CAS: 86798-87-0
• 化学式: C₁₄H₁₂N₄O
• 分子量: 252.275
• InChiKey: BNVJIFFGBXDZTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4,5-dihydro-6-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone 在 溴 作用下， 以 溶剂黄146 为溶剂， 生成 6-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone
  参考文献：
  名称：

  Substituted

  摘要：

  4,5-二氢-6-[4-(1H-咪唑-1-基)-苯基]-3(2H)-吡啶啉化合物和6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶啉化合物及其药用盐可用作心力衰竭药物。这些化合物可在麻醉狗体内显著增加心肌收缩力。这些化合物是通过将取代的γ-氧代苯丁酸与适当取代的肼反应而制备的，从而得到4,5-二氢-6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶啉，然后将其脱氢为6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶啉。中间体4,5-二氢-6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶啉和6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶啉均可用作心力衰竭药物。

  公开号：

  US04353905A1

文献信息

• Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and
  申请人：Warner-Lambert Company

  公开号：US04734415A1

  公开（公告）日：1988-03-29

  Substituted 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinone compounds and 6-(substituted)phenyl-3(2H)-pyridazinone compounds and pharmaceutically acceptable salts thereof are useful as cardiotonic and antihypertensive agents. Said compounds cause a significant increase in myocardial contractility in the dog. Said compounds also cause a decrease in blood pressure in the spontaneously hypertensive rat. Said compounds are produced by reacting substituted .gamma.-oxobenzenebutanoic acids with suitably substituted hydrazines to provide 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinones which are dehydrogenated to 6-(substituted)phenyl-3(2H)-pyridazinones. Both the intermediate 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinones and the 6-(substituted)phenyl-3(2H)-pyridazinones are useful as cardiotonic and antihypertensive agents.

  4,5-二氢-6-(取代基)苯基-3(2H)-吡啶并酮化合物和6-(取代基)苯基-3(2H)-吡啶并酮化合物及其药用盐可作为强心和降压药物。这些化合物在狗体内可显著增加心肌收缩力。这些化合物还可导致自发性高血压大鼠的血压降低。这些化合物是通过将取代的γ-氧基苯丁酸与适当取代的肼反应制备的，从而提供4,5-二氢-6-(取代基)苯基-3(2H)-吡啶并酮，然后将其脱氢为6-(取代基)苯基-3(2H)-吡啶并酮。中间体4,5-二氢-6-(取代基)苯基-3(2H)-吡啶并酮和6-(取代基)苯基-3(2H)-吡啶并酮均可作为强心和降压药物。
• Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted)phenyl-3(2H)-pyridazinones
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0075436A1

  公开（公告）日：1983-03-30

  Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinone compounds and 6-(substituted)phenyl-3(2H)-pyridazinone compounds and pharmaceutically acceptable salts thereof are useful as cardiotonic and antihypertensive agents. Said compounds cause a significant increase in myocardial contractility in the dog. Said compounds also cause a decrease in blood pressure in the spontaneously hypertensive rat. Said compounds are produced by reacting substituted y-oxobenzene-butanoic acids with suitably substituted hydrazines to provide 4,5-dihydro-6-(substituted)phenyl-3(2H)-pyridazinones which are dehydrogenated to 6-(substituted)phenyl-3(2H)-pyridazinones. Both the 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and the 6-(substituted)-phenyl-3(2H)-pyridazinones are useful as cardiotonic and antihypertensive agents. The compounds have the formula: where represents a double or single bond and A is anyone of five types of heterocyclic ring-containing radicals, and R2, R3 and Y are hydrogen or various substituents.

  取代的 4,5-二氢-6-(取代)苯基-3(2H)-哒嗪酮化合物和 6-(取代)苯基-3(2H)-哒嗪酮化合物及其药学上可接受的盐类可用作强心剂和降压药。 上述化合物可显著增强狗的心肌收缩力。所述化合物还能降低自发性高血压大鼠的血压。所述化合物是通过取代的 y-氧代苯丁酸与适当取代的肼反应生成 4,5-二氢-6-（取代）苯基-3(2H)-哒嗪酮，后者脱氢生成 6-（取代）苯基-3(2H)-哒嗪酮。 4,5-二氢-6-（取代）苯基-3(2H)-哒嗪酮和 6-（取代）苯基-3(2H)-哒嗪酮均可用作强心剂和降压药。这些化合物的化学式如下 其中代表双键或单键，A 是五种含杂环基中的任何一种，R2、R3 和 Y 是氢或各种取代基。
• US4353905A
  申请人：——

  公开号：US4353905A

  公开（公告）日：1982-10-12
• US4734415A
  申请人：——

  公开号：US4734415A

  公开（公告）日：1988-03-29
• Substituted
  申请人：Warner-Lambert Company

  公开号：US04353905A1

  公开（公告）日：1982-10-12

  Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)-phenyl]-3(2H)-pyridazinone compounds and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinone compounds and pharmaceutically acceptable salts thereof are useful as cardiotonic agents. Said compounds cause a significant increase in myocardial contractility in the anesthetized dog. Said compounds are produced by reacting substituted .gamma.-oxo-benzenebutanoic acids with suitably substituted hydrazines to provide 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones which are dehydrogenated to 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones. Both the intermediate 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and the 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones are useful as cardiotonic agents.

  4,5-二氢-6-[4-(1H-咪唑-1-基)-苯基]-3(2H)-吡啶啉化合物和6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶啉化合物及其药用盐可用作心力衰竭药物。这些化合物可在麻醉狗体内显著增加心肌收缩力。这些化合物是通过将取代的γ-氧代苯丁酸与适当取代的肼反应而制备的，从而得到4,5-二氢-6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶啉，然后将其脱氢为6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶啉。中间体4,5-二氢-6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶啉和6-[4-(1H-咪唑-1-基)苯基]-3(2H)-吡啶啉均可用作心力衰竭药物。